In extending these findings to PC tissues, we found that MUC1 is amplified in 29.9% (32/107) of a NEPC enriched CRPC cohort9, compared to 6.0% (9/150) in the SU2C CRPC cohort with minimal NEPC50 and 1.8% (6/333) in the TCGA primary prostate adenocarcinoma cohort51 (Fig. 8a). This evidence concerns the gene MUC1 and prostate adenocarcinoma.